HomeGreater Than Icon
Astrazeneca Pharma India LtdGreater Than Icon
Astrazeneca Pharma India Ltd Financials
Company Logo

Astrazeneca Pharma India Ltd Financial Statement

Astrazeneca Pharma India Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue395.87
Operating Expense407.01
Net Profit-11.79
Net Profit Margin-2.98
Earning Per Share-4.72
EBIDTA2.98
Effective Tax Rate-96.50

Astrazeneca Pharma India Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,295.53
Operating Expenses Annual1,111.08
Operating Profit Annual235.68
Interest Annual1.20
Depreciation14.81
Net Profit Annual161.51
Tax Annual58.03

Astrazeneca Pharma India Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning500.34
Cash Flow from Operations27.87
Cash Flow from Investing21.74
Cash Flow from Financing-44.38
Cash Flow at the End505.57

Astrazeneca Pharma India Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)18.19
PBIT Margin (%)17.04
PBT Margin (%)2.84
Net PROFIT Margin (%)12.47
Return On Networth / Equity (%)24.84
Return On Networth /Employed (%)33.26
Return On Assets (%)24.31
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.95

Astrazeneca Pharma India Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual66.68
Total Current Assets Annual932.71
Non Current Assets Annual145.32
Total Shareholders Funds Annual711.92
Total Assets Annual1,078.03

Astrazeneca Pharma India Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Sep 19, 2024, Astrazeneca Pharma India Ltd has a market capitalization of 13,301 Cr. Value Research classifies it as a Large-Cap company.
Yes, Astrazeneca Pharma India Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Astrazeneca Pharma India Ltd recorded a total revenue of approximately 1,295.53 Cr marking a significant milestone in the company's financial performance.
Astrazeneca Pharma India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.2% annually, respectively..
Astrazeneca Pharma India Ltd's current PE ratio is 82.35.
Astrazeneca Pharma India Ltd's ROCE averaged 25.4% from the FY ending March 2022 to 2024, with a median of 29.4%. It peaked at 30.8% in March 2024, reflecting strong capital efficiency over the period..
Astrazeneca Pharma India Ltd's latest EBIT is Rs. 220.74 Cr, surpassing the average EBIT of Rs. 146.49 Cr over the 5 years..